Cosmo pharmaceuticals
Uceris® / Cortiment®

Uceris® / Cortiment®

Uceris®/Cortiment® is an oral tablet formulation which delivers budesonide directly to the lumen of the colon. Budesonide is a corticosteroid that acts as an anti-inflammatory pharmaceutical product.

Uceris®/Cortiment® is prescription-only and is used to help get active, mild to moderate Ulcerative Colitis under control (induce remission) and may help relieve the symptoms of ulcerative colitis.

The specific pharmaceutical product dissolution profile increases the colonic-specific bio-availability of budesonide and reduces the pre-colonic systemic absorption.

The intended reduction of systemic absorption reduces side effects associated with pharmaceutical product treatment, while the intended delivery to the colon enables the product to be especially effective in the treatment of proximal and distal ulcerative colitis.

Through the application of our MMX® technology to budesonide, an off-patent corticosteroid, Cosmo has developed a treatment which is more effective than existing 5-ASA applications and less toxic than classical corticosteroid applications.

Uceris® is licensed to Bausch Health in the U.S. In July 2018, the FDA approved a generic version of Uceris.

Cortiment® is licensed to Ferring in EU and the rest of the world.

Click here for more details including safety and prescribing information.